Imfinzi
Manufacturing · United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.imfinzihcp.comRevenue
$6.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Imfinzi
IMFINZI is a leading immunotherapy treatment, primarily focusing on various types of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The drug durvalumab is prominently featured as a stringently recommended therapy option, categorized as Category 1 by the National Comprehensive Cancer Network (NCCN) for several oncological indications. The intended clients include healthcare professionals and patients dealing with advanced cancer stages, providing critical support resources and guidelines for treatment. IMFINZI also extends its offerings to other malignancies, such as biliary tract cancers and hepatocellular carcinoma, showcasing its multifaceted approach in cancer therapy.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imfinzi your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Imfinzi launches new products
Congratulate Masked Content for being promoted to Masked Content at Imfinzi
Imfinzi, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Imfinzi has new funding data
Click to see if Imfinzi had a recent Job posting/layoffs
Check if Imfinzi has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Imfinzi recently announced quarterly report
Check out if Imfinzi is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Imfinzi as Masked Content
Find 3 more new buyers
Compare Similar Companies to Imfinzi
Compare insights from companies similar to Imfinzi, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Imfinzi
$6.7M
1-10
Private
-
-
N/A
Company Profile Activity
Activity Insights
Imfinzi is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Imfinzi is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Imfinzi.
Imfinzi Tech Stack
A closer look at the technologies used by Imfinzi
Imfinzi News & Media
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant chemotherapy with radical cystectomy alone in patients with or without a pathologic complete response (pCR) in muscle-invasive bladder cancer (MIBC). PatientsIMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with IMFINZI in combinationIMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT. Small cell lung cancer (SCLYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® (olaparib), IMFINZI® (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutat
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Imfinzi
Sign Up For FreeTo access detailed company insights
IMFINZI is a leading immunotherapy treatment, primarily focusing on various types of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The drug durvalumab is prominently featured as a stringently recommended therapy option, categorized as Category 1 by the National Comprehensive Cancer Network (NCCN) for s... Read More
